Review



human pdgf-bb antibody  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Bio-Techne corporation human pdgf-bb antibody
    Human Pdgf Bb Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 92/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf-bb+antibody/bio-techne+corporation___af-220-na?v=Bio-Techne+corporation
    Average 92 stars, based on 33 article reviews
    human pdgf-bb antibody - by Bioz Stars, 2026-07
    92/100 stars

    Images



    Similar Products

    92
    Bio-Techne corporation human pdgf-bb antibody
    Human Pdgf Bb Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf-bb+antibody/bio-techne+corporation___af-220-na?v=Bio-Techne+corporation
    Average 92 stars, based on 1 article reviews
    human pdgf-bb antibody - by Bioz Stars, 2026-07
    92/100 stars
      Buy from Supplier

    93
    R&D Systems pdgf bb
    Measurements of total protein and growth factors released from hPLG and xPMC/hPLG. (A) Cumulative release percentage of total protein over a 4 day period, determined by BCA assay. (B) SDS-PAGE analysis results of the PBS supernatants collected over a 4 day period, stained with Coomassie blue. Cumulative release of (C) TGF-β1 and <t>(D)</t> <t>PDGF-BB</t> over a 3 day period. (E) Total protein contents found in the PBS supernatants of hPLG and hPLG combined with either PM or xCMC, assessed after a 2 day incubation. Data are expressed as mean ± SD ( n = 3). * p < 0.05, ** p < 0.01. Statistical significance in (C,D) was analyzed at the same time point.
    Pdgf Bb, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf-bb+antibody/pmc13019196-117-30-34?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    pdgf bb - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    R&D Systems antibodies against pdgf bb
    Measurements of total protein and growth factors released from hPLG and xPMC/hPLG. (A) Cumulative release percentage of total protein over a 4 day period, determined by BCA assay. (B) SDS-PAGE analysis results of the PBS supernatants collected over a 4 day period, stained with Coomassie blue. Cumulative release of (C) TGF-β1 and <t>(D)</t> <t>PDGF-BB</t> over a 3 day period. (E) Total protein contents found in the PBS supernatants of hPLG and hPLG combined with either PM or xCMC, assessed after a 2 day incubation. Data are expressed as mean ± SD ( n = 3). * p < 0.05, ** p < 0.01. Statistical significance in (C,D) was analyzed at the same time point.
    Antibodies Against Pdgf Bb, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf-bb+antibody/pm40081225-294-4-10?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    antibodies against pdgf bb - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    R&D Systems antibody against human pdgf bb
    Effects of bone cements on the cytokine production assessed by ELISA. Human PRP was added to the individual bone cements at 37 °C for 60 min, and the levels of <t>PDGF-BB,</t> TGF-β1, PF-4, and SDF-1α were quantified using ELISA. Data are expressed as mean ± SD from three different single-donor PRP samples. p < 0.05.
    Antibody Against Human Pdgf Bb, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf-bb+antibody/pmc11907285-118-2-7?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    antibody against human pdgf bb - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    92
    R&D Systems human pdgf bb
    Effects of bone cements on the cytokine production assessed by ELISA. Human PRP was added to the individual bone cements at 37 °C for 60 min, and the levels of <t>PDGF-BB,</t> TGF-β1, PF-4, and SDF-1α were quantified using ELISA. Data are expressed as mean ± SD from three different single-donor PRP samples. p < 0.05.
    Human Pdgf Bb, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf-bb+antibody/pm38218061-63-35-41?v=R%26D+Systems
    Average 92 stars, based on 1 article reviews
    human pdgf bb - by Bioz Stars, 2026-07
    92/100 stars
      Buy from Supplier

    93
    R&D Systems biotinylated antibodies
    Effects of bone cements on the cytokine production assessed by ELISA. Human PRP was added to the individual bone cements at 37 °C for 60 min, and the levels of <t>PDGF-BB,</t> TGF-β1, PF-4, and SDF-1α were quantified using ELISA. Data are expressed as mean ± SD from three different single-donor PRP samples. p < 0.05.
    Biotinylated Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf-bb+antibody/us11732029-1030-6-14?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    biotinylated antibodies - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    99
    R&D Systems human pdgf bb duoset elisa de r d systems dy220
    Mean ± SD of platelet (PLT) concentrations, mean platelet volume (MPV), erythrocytes (RBCs), leukocytes (WBC), lymphocytes (LYMPH), neutrophils (NFS), and monocytes (MON) concentrations in whole blood (WB) samples and in the PRP and PPP fractions; platelet-derived growth factor <t> BB (PDGF-BB) </t> and transforming growth factor B1 (TGF-β1) concentrations in the PRP and PPP fractions in 11 FeLV cats ( n = 11).
    Human Pdgf Bb Duoset Elisa De R D Systems Dy220, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf-bb+antibody/pmc09909748-120-33-38?v=R%26D+Systems
    Average 99 stars, based on 1 article reviews
    human pdgf bb duoset elisa de r d systems dy220 - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    93
    R&D Systems anti human pdgf bb polyclonal antibody
    Figure 2. Purification of peptide and recombinant proteins. (a) RP-HPLC analysis of purified GHRP-6 and MTD-GHRP-6 peptides using the 20–60% solvent B gradient method for 25 min. (b) SDS-PAGE and western blot analysis of des(1-3)IGF-I and MTD-des(1-3)IGF-I proteins, (c) SDS-PAGE and western blot analysis of <t>PDGF-BB</t> and MTD-PDGF-BB proteins. M, molecular weight marker; R, reduced form; NR, non-reduced form; *, blank lane without sample loading. The raw data of western blot analysis in (b) and (c), respectively, were presented in Supplementary Information as Fig. S4a,b.
    Anti Human Pdgf Bb Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdgf-bb+antibody/pm35760980-201-39-43?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    anti human pdgf bb polyclonal antibody - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    Image Search Results


    Measurements of total protein and growth factors released from hPLG and xPMC/hPLG. (A) Cumulative release percentage of total protein over a 4 day period, determined by BCA assay. (B) SDS-PAGE analysis results of the PBS supernatants collected over a 4 day period, stained with Coomassie blue. Cumulative release of (C) TGF-β1 and (D) PDGF-BB over a 3 day period. (E) Total protein contents found in the PBS supernatants of hPLG and hPLG combined with either PM or xCMC, assessed after a 2 day incubation. Data are expressed as mean ± SD ( n = 3). * p < 0.05, ** p < 0.01. Statistical significance in (C,D) was analyzed at the same time point.

    Journal: ACS Omega

    Article Title: In Vitro Enhanced Performance of Human Platelet Lysate Gel Integrated with Mesoporous Silica Nanoparticle/Carboxymethyl Chitosan Composite Hydrogel: Structural Stability and Biological Activities for Chronic Wound Healing

    doi: 10.1021/acsomega.5c13494

    Figure Lengend Snippet: Measurements of total protein and growth factors released from hPLG and xPMC/hPLG. (A) Cumulative release percentage of total protein over a 4 day period, determined by BCA assay. (B) SDS-PAGE analysis results of the PBS supernatants collected over a 4 day period, stained with Coomassie blue. Cumulative release of (C) TGF-β1 and (D) PDGF-BB over a 3 day period. (E) Total protein contents found in the PBS supernatants of hPLG and hPLG combined with either PM or xCMC, assessed after a 2 day incubation. Data are expressed as mean ± SD ( n = 3). * p < 0.05, ** p < 0.01. Statistical significance in (C,D) was analyzed at the same time point.

    Article Snippet: To unequivocally determine the role of PDGF-BB specifically as a primary GF mediating hPL-induced periodontal fibroblast migration, PDGF-BB activity was inhibited by preincubating xPMC/hPLG spots with 0.2 μg/mL of a PDGF-BB neutralizing antibody (AF-220-NA, R&D Systems) for 45 min. As a negative control, xPMC/hPLG spots were pretreated for 45 min with an isotype control goat IgG antibody (0.2 μg/mL; AB-108 C, R&D Systems).

    Techniques: BIA-KA, SDS Page, Staining, Incubation

    Effect of xPMC/hPLG on the migration of periodontal fibroblasts. (A) Cells were seeded and exposed to chemokines from different gel spots for 6 h. The migratory cells surrounding the edge of gel spots of (i) hPPG, (ii) hPLG, (iii) xPMC/hPLG, (iv) xPMC/hPLG pretreated with IgG isotype control antibody (Ab), and (v) xPMC/hPLG pretreated with neutralizing antibody (nAb) against PDGF-BB were stained with crystal violet (A), and the cell density (cells/mm 2 ) was quantified from the number of cells that migrated close to each gel spot within a 500 μm radial distance from the gel edge (B). The results are expressed as mean ± SD ( n = 8). Different letters indicate significant differences ( p < 0.05).

    Journal: ACS Omega

    Article Title: In Vitro Enhanced Performance of Human Platelet Lysate Gel Integrated with Mesoporous Silica Nanoparticle/Carboxymethyl Chitosan Composite Hydrogel: Structural Stability and Biological Activities for Chronic Wound Healing

    doi: 10.1021/acsomega.5c13494

    Figure Lengend Snippet: Effect of xPMC/hPLG on the migration of periodontal fibroblasts. (A) Cells were seeded and exposed to chemokines from different gel spots for 6 h. The migratory cells surrounding the edge of gel spots of (i) hPPG, (ii) hPLG, (iii) xPMC/hPLG, (iv) xPMC/hPLG pretreated with IgG isotype control antibody (Ab), and (v) xPMC/hPLG pretreated with neutralizing antibody (nAb) against PDGF-BB were stained with crystal violet (A), and the cell density (cells/mm 2 ) was quantified from the number of cells that migrated close to each gel spot within a 500 μm radial distance from the gel edge (B). The results are expressed as mean ± SD ( n = 8). Different letters indicate significant differences ( p < 0.05).

    Article Snippet: To unequivocally determine the role of PDGF-BB specifically as a primary GF mediating hPL-induced periodontal fibroblast migration, PDGF-BB activity was inhibited by preincubating xPMC/hPLG spots with 0.2 μg/mL of a PDGF-BB neutralizing antibody (AF-220-NA, R&D Systems) for 45 min. As a negative control, xPMC/hPLG spots were pretreated for 45 min with an isotype control goat IgG antibody (0.2 μg/mL; AB-108 C, R&D Systems).

    Techniques: Migration, Control, Staining

    Schematic image of the proposed concentration-dependent biphasic effect of xPMC/hPLG on the chemotaxis and cell doubling of periodontal fibroblasts. Color gradient represents a concentration gradient from high (red) to low (blue) concentrations of hPL-derived mediators released from the xPMC/hPLG hydrogel. The hydrogel gave rise to a concentration gradient of a GF, i.e., PDGF-BB, declining with increasing distance away from the hydrogel. Fibroblasts in Area 2 were exposed to a low concentration of PDGF-BB sufficient to induce their migration toward the hydrogel. As the cells ascended the concentration gradient, the signal for chemotaxis was switched off, but the signal for cell division was switched on, thereby resulting in the presence of proliferating cells at Area 1, adjacent to the hydrogel.

    Journal: ACS Omega

    Article Title: In Vitro Enhanced Performance of Human Platelet Lysate Gel Integrated with Mesoporous Silica Nanoparticle/Carboxymethyl Chitosan Composite Hydrogel: Structural Stability and Biological Activities for Chronic Wound Healing

    doi: 10.1021/acsomega.5c13494

    Figure Lengend Snippet: Schematic image of the proposed concentration-dependent biphasic effect of xPMC/hPLG on the chemotaxis and cell doubling of periodontal fibroblasts. Color gradient represents a concentration gradient from high (red) to low (blue) concentrations of hPL-derived mediators released from the xPMC/hPLG hydrogel. The hydrogel gave rise to a concentration gradient of a GF, i.e., PDGF-BB, declining with increasing distance away from the hydrogel. Fibroblasts in Area 2 were exposed to a low concentration of PDGF-BB sufficient to induce their migration toward the hydrogel. As the cells ascended the concentration gradient, the signal for chemotaxis was switched off, but the signal for cell division was switched on, thereby resulting in the presence of proliferating cells at Area 1, adjacent to the hydrogel.

    Article Snippet: To unequivocally determine the role of PDGF-BB specifically as a primary GF mediating hPL-induced periodontal fibroblast migration, PDGF-BB activity was inhibited by preincubating xPMC/hPLG spots with 0.2 μg/mL of a PDGF-BB neutralizing antibody (AF-220-NA, R&D Systems) for 45 min. As a negative control, xPMC/hPLG spots were pretreated for 45 min with an isotype control goat IgG antibody (0.2 μg/mL; AB-108 C, R&D Systems).

    Techniques: Concentration Assay, Chemotaxis Assay, Derivative Assay, Migration

    Effects of bone cements on the cytokine production assessed by ELISA. Human PRP was added to the individual bone cements at 37 °C for 60 min, and the levels of PDGF-BB, TGF-β1, PF-4, and SDF-1α were quantified using ELISA. Data are expressed as mean ± SD from three different single-donor PRP samples. p < 0.05.

    Journal: ACS Materials Au

    Article Title: Platelet Responses to Urethane Dimethacrylate-Based Bone Cements Containing Monocalcium Phosphate/ε-Polylysine: Role of ε-Polylysine in In Vitro Wound Healing Induced by Platelet-Derived Growth Factor-BB

    doi: 10.1021/acsmaterialsau.4c00143

    Figure Lengend Snippet: Effects of bone cements on the cytokine production assessed by ELISA. Human PRP was added to the individual bone cements at 37 °C for 60 min, and the levels of PDGF-BB, TGF-β1, PF-4, and SDF-1α were quantified using ELISA. Data are expressed as mean ± SD from three different single-donor PRP samples. p < 0.05.

    Article Snippet: The neutralizing antibody against human PDGF-BB (#AF-220-NA, R&D systems) or an isotype control antibody (final concentration at 500 ng/mL) was added to pretreat the bone-cement-exposed PRP for 1 h before being used to supplement the culture medium for the scratch-based wound healing assay.

    Techniques: Enzyme-linked Immunosorbent Assay

    Effect of PDGF-BB neutralizing antibody on the bone-cement-exposed conditioned media-induced in vitro MSC-mediated wound healing. Human PRP was incubated with the different bone cements for 1 h, and the cell-free conditioned plasma samples were used in the scratch-based wound healing assay with either isotype control or PDGF-BB neutralizing antibodies for indicated times. Data are expressed as mean ± SD from three different single-donor PRP samples. p < 0.05.

    Journal: ACS Materials Au

    Article Title: Platelet Responses to Urethane Dimethacrylate-Based Bone Cements Containing Monocalcium Phosphate/ε-Polylysine: Role of ε-Polylysine in In Vitro Wound Healing Induced by Platelet-Derived Growth Factor-BB

    doi: 10.1021/acsmaterialsau.4c00143

    Figure Lengend Snippet: Effect of PDGF-BB neutralizing antibody on the bone-cement-exposed conditioned media-induced in vitro MSC-mediated wound healing. Human PRP was incubated with the different bone cements for 1 h, and the cell-free conditioned plasma samples were used in the scratch-based wound healing assay with either isotype control or PDGF-BB neutralizing antibodies for indicated times. Data are expressed as mean ± SD from three different single-donor PRP samples. p < 0.05.

    Article Snippet: The neutralizing antibody against human PDGF-BB (#AF-220-NA, R&D systems) or an isotype control antibody (final concentration at 500 ng/mL) was added to pretreat the bone-cement-exposed PRP for 1 h before being used to supplement the culture medium for the scratch-based wound healing assay.

    Techniques: In Vitro, Incubation, Clinical Proteomics, Wound Healing Assay, Control

    Mean ± SD of platelet (PLT) concentrations, mean platelet volume (MPV), erythrocytes (RBCs), leukocytes (WBC), lymphocytes (LYMPH), neutrophils (NFS), and monocytes (MON) concentrations in whole blood (WB) samples and in the PRP and PPP fractions; platelet-derived growth factor  BB (PDGF-BB)  and transforming growth factor B1 (TGF-β1) concentrations in the PRP and PPP fractions in 11 FeLV cats ( n = 11).

    Journal: Frontiers in Veterinary Science

    Article Title: Evaluation of Platelet-Rich Plasma by means of PRGF ® -Endoret ® protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation

    doi: 10.3389/fvets.2023.1110055

    Figure Lengend Snippet: Mean ± SD of platelet (PLT) concentrations, mean platelet volume (MPV), erythrocytes (RBCs), leukocytes (WBC), lymphocytes (LYMPH), neutrophils (NFS), and monocytes (MON) concentrations in whole blood (WB) samples and in the PRP and PPP fractions; platelet-derived growth factor BB (PDGF-BB) and transforming growth factor B1 (TGF-β1) concentrations in the PRP and PPP fractions in 11 FeLV cats ( n = 11).

    Article Snippet: The concentrations of both GFs in both plasma fractions (PPP and PRP) were determined using an ELISA kit of development with antibodies to human (Human TGF-beta1 DuoSet ELISA de R&D Systems DY240-05 and Human PDGF-BB DuoSet ELISA de R&D Systems DY220, respectively), following the methodology previously published by Miguel-Pastor et al. ( ).

    Techniques:

    Comparison of Platelet-Derived Growth Factor-BB [PDGF-BB; (A) ] and transforming growth factor ß1 [TGF-ß1; (B) ] concentrations (mean ± SD) in FeLV cats ( n = 11) between PRP and PPP fractions. Different letters (a, b) indicate differences between groups. P < 0.05 statistically different.

    Journal: Frontiers in Veterinary Science

    Article Title: Evaluation of Platelet-Rich Plasma by means of PRGF ® -Endoret ® protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation

    doi: 10.3389/fvets.2023.1110055

    Figure Lengend Snippet: Comparison of Platelet-Derived Growth Factor-BB [PDGF-BB; (A) ] and transforming growth factor ß1 [TGF-ß1; (B) ] concentrations (mean ± SD) in FeLV cats ( n = 11) between PRP and PPP fractions. Different letters (a, b) indicate differences between groups. P < 0.05 statistically different.

    Article Snippet: The concentrations of both GFs in both plasma fractions (PPP and PRP) were determined using an ELISA kit of development with antibodies to human (Human TGF-beta1 DuoSet ELISA de R&D Systems DY240-05 and Human PDGF-BB DuoSet ELISA de R&D Systems DY220, respectively), following the methodology previously published by Miguel-Pastor et al. ( ).

    Techniques: Comparison, Derivative Assay

    Figure 2. Purification of peptide and recombinant proteins. (a) RP-HPLC analysis of purified GHRP-6 and MTD-GHRP-6 peptides using the 20–60% solvent B gradient method for 25 min. (b) SDS-PAGE and western blot analysis of des(1-3)IGF-I and MTD-des(1-3)IGF-I proteins, (c) SDS-PAGE and western blot analysis of PDGF-BB and MTD-PDGF-BB proteins. M, molecular weight marker; R, reduced form; NR, non-reduced form; *, blank lane without sample loading. The raw data of western blot analysis in (b) and (c), respectively, were presented in Supplementary Information as Fig. S4a,b.

    Journal: Scientific reports

    Article Title: Efficient transdermal delivery of functional protein cargoes by a hydrophobic peptide MTD 1067.

    doi: 10.1038/s41598-022-14463-9

    Figure Lengend Snippet: Figure 2. Purification of peptide and recombinant proteins. (a) RP-HPLC analysis of purified GHRP-6 and MTD-GHRP-6 peptides using the 20–60% solvent B gradient method for 25 min. (b) SDS-PAGE and western blot analysis of des(1-3)IGF-I and MTD-des(1-3)IGF-I proteins, (c) SDS-PAGE and western blot analysis of PDGF-BB and MTD-PDGF-BB proteins. M, molecular weight marker; R, reduced form; NR, non-reduced form; *, blank lane without sample loading. The raw data of western blot analysis in (b) and (c), respectively, were presented in Supplementary Information as Fig. S4a,b.

    Article Snippet: After SDS-PAGE, the proteins were transferred to the PVDF membrane (300 mA, 1 h), which was blocked using 5% skim milk for 1 h. In the reaction with the primary antibodies, anti-human IGF1 monoclonal antibody (R&D Systems, USA) and anti-human PDGF-BB polyclonal antibody (R&D Systems, USA), respectively, were used for incubation 16 h at 4 °C.

    Techniques: Purification, Recombinant, Solvent, SDS Page, Western Blot, Molecular Weight, Marker

    Figure 6. Transdermal delivery of MTD 1067-conjugated peptide and recombinant proteins in artificial skin model. Comparison of skin penetration (left) and permeability analysis using fluorescence intensity on the confocal image (right) were made with (a) FITC-labeled GHRP-6 and MTD-GHRP-6, (b) FITC-labeled des(1-3)IGF-I and MTD-des(1-3)IGF-I, (c) Rhodamine-labeled PDGF-BB and MTD-PDGF-BB. Each of the fluorescence intensity values per equivalent area are expressed as mean ± S.E. based on analysis of at least three independent images. Asterisks indicate statistical significance compared with the cargo control, as determined by the student’s t-test (*p < 0.05, **p < 0.01, ***p < 0.001).

    Journal: Scientific reports

    Article Title: Efficient transdermal delivery of functional protein cargoes by a hydrophobic peptide MTD 1067.

    doi: 10.1038/s41598-022-14463-9

    Figure Lengend Snippet: Figure 6. Transdermal delivery of MTD 1067-conjugated peptide and recombinant proteins in artificial skin model. Comparison of skin penetration (left) and permeability analysis using fluorescence intensity on the confocal image (right) were made with (a) FITC-labeled GHRP-6 and MTD-GHRP-6, (b) FITC-labeled des(1-3)IGF-I and MTD-des(1-3)IGF-I, (c) Rhodamine-labeled PDGF-BB and MTD-PDGF-BB. Each of the fluorescence intensity values per equivalent area are expressed as mean ± S.E. based on analysis of at least three independent images. Asterisks indicate statistical significance compared with the cargo control, as determined by the student’s t-test (*p < 0.05, **p < 0.01, ***p < 0.001).

    Article Snippet: After SDS-PAGE, the proteins were transferred to the PVDF membrane (300 mA, 1 h), which was blocked using 5% skim milk for 1 h. In the reaction with the primary antibodies, anti-human IGF1 monoclonal antibody (R&D Systems, USA) and anti-human PDGF-BB polyclonal antibody (R&D Systems, USA), respectively, were used for incubation 16 h at 4 °C.

    Techniques: Recombinant, Comparison, Permeability, Fluorescence, Labeling, Control